Rohrabaugh et al. supported this concept, showing that in vivo inhibition of MEK1/2 by Trametinib in a murine CNL model expressing compound CSF3R mutations effectively abrogated leukemia development123. This evidence concerns the gene MAP2K1 and chronic neutrophilic leukemia.